Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 4
2011 8
2012 5
2013 4
2014 4
2015 4
2016 7
2017 1
2018 3
2019 4
2020 2
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Daver NG, et al. Among authors: kelly kr. Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362. Blood. 2023. PMID: 36265087 Free PMC article. Clinical Trial.
Oncolytic Viruses for Multiple Myeloma Therapy.
Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST. Calton CM, et al. Among authors: kelly kr. Cancers (Basel). 2018 Jun 14;10(6):198. doi: 10.3390/cancers10060198. Cancers (Basel). 2018. PMID: 29903988 Free PMC article. Review.
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.
Nawrocki ST, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, Colombo A, Coffey M, Fernandez Hernandez E, Chen X, Nuovo GJ, Carew JS, Mohrbacher AF, Fields P, Kuhn P, Siddiqi I, Merchant A, Kelly KR. Nawrocki ST, et al. Among authors: kelly kr. Clin Cancer Res. 2023 Dec 15;29(24):5087-5103. doi: 10.1158/1078-0432.CCR-23-0229. Clin Cancer Res. 2023. PMID: 37812476 Free PMC article. Clinical Trial.
Targeting aurora kinases in cancer treatment.
Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS. Kelly KR, et al. Curr Drug Targets. 2011 Dec;12(14):2067-78. doi: 10.2174/138945011798829410. Curr Drug Targets. 2011. PMID: 21777198 Review.
Mechanisms of mTOR inhibitor resistance in cancer therapy.
Carew JS, Kelly KR, Nawrocki ST. Carew JS, et al. Among authors: kelly kr. Target Oncol. 2011 Mar;6(1):17-27. doi: 10.1007/s11523-011-0167-8. Epub 2011 Mar 9. Target Oncol. 2011. PMID: 21547705 Review.
Emerging drugs in the treatment of pancreatic cancer.
Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Mahalingam D, et al. Among authors: kelly kr. Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502. Expert Opin Emerg Drugs. 2009. PMID: 19466902 Review.
The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine.
Nawrocki ST, Han Y, Visconte V, Przychodzen B, Espitia CM, Phillips J, Anwer F, Advani A, Carraway HE, Kelly KR, Sekeres MA, Maciejewski JP, Carew JS. Nawrocki ST, et al. Among authors: kelly kr. Leukemia. 2019 Dec;33(12):2971-2974. doi: 10.1038/s41375-019-0529-2. Epub 2019 Jul 29. Leukemia. 2019. PMID: 31358855 Free PMC article. No abstract available.
44 results